Cargando…
Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development
The main factors influencing the absorption of orally administered drugs are solubility and permeability, which are location-dependent and may vary along the gastrointestinal tract (GIT). The purpose of this work was to investigate segmental-dependent intestinal absorption and its role in controlled...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151103/ https://www.ncbi.nlm.nih.gov/pubmed/32214015 http://dx.doi.org/10.3390/pharmaceutics12030295 |
_version_ | 1783521172965556224 |
---|---|
author | Markovic, Milica Zur, Moran Fine-Shamir, Noa Haimov, Ester González-Álvarez, Isabel Dahan, Arik |
author_facet | Markovic, Milica Zur, Moran Fine-Shamir, Noa Haimov, Ester González-Álvarez, Isabel Dahan, Arik |
author_sort | Markovic, Milica |
collection | PubMed |
description | The main factors influencing the absorption of orally administered drugs are solubility and permeability, which are location-dependent and may vary along the gastrointestinal tract (GIT). The purpose of this work was to investigate segmental-dependent intestinal absorption and its role in controlled-release (CR) drug product development. The solubility/dissolution and permeability of carvedilol (vs. metoprolol) were thoroughly studied, in vitro/in vivo (Octanol-buffer distribution coefficients (Log D), parallel artificial membrane permeability assay (PAMPA), rat intestinal perfusion), focusing on location-dependent effects. Carvedilol exhibits changing solubility in different conditions throughout the GIT, attributable to its zwitterionic nature. A biorelevant pH-dilution dissolution study for carvedilol immediate release (IR) vs. CR scenario elucidates that while the IR dose (25 mg) may dissolve in the GIT luminal conditions, higher doses used in CR products would precipitate if administered at once, highlighting the advantage of CR from the solubility/dissolution point of view. Likewise, segmental-dependent permeability was evident, with higher permeability of carvedilol vs. the low/high P(eff) marker metoprolol throughout the GIT, confirming it as a biopharmaceutical classification system (BCS) class II drug. Theoretical analysis of relevant physicochemical properties confirmed these results as well. A CR product may shift the carvedilol’s solubility behavior from class II to I since only a small dose portion needs to be solubilized at a given time point. The permeability of carvedilol surpasses the threshold of metoprolol jejunal permeability throughout the entire GIT, including the colon, establishing it as a suitable candidate for CR product development. Altogether, this work may serve as an analysis model in the decision process of CR formulation development and may increase our biopharmaceutical understanding of a successful CR drug product. |
format | Online Article Text |
id | pubmed-7151103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71511032020-04-20 Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development Markovic, Milica Zur, Moran Fine-Shamir, Noa Haimov, Ester González-Álvarez, Isabel Dahan, Arik Pharmaceutics Article The main factors influencing the absorption of orally administered drugs are solubility and permeability, which are location-dependent and may vary along the gastrointestinal tract (GIT). The purpose of this work was to investigate segmental-dependent intestinal absorption and its role in controlled-release (CR) drug product development. The solubility/dissolution and permeability of carvedilol (vs. metoprolol) were thoroughly studied, in vitro/in vivo (Octanol-buffer distribution coefficients (Log D), parallel artificial membrane permeability assay (PAMPA), rat intestinal perfusion), focusing on location-dependent effects. Carvedilol exhibits changing solubility in different conditions throughout the GIT, attributable to its zwitterionic nature. A biorelevant pH-dilution dissolution study for carvedilol immediate release (IR) vs. CR scenario elucidates that while the IR dose (25 mg) may dissolve in the GIT luminal conditions, higher doses used in CR products would precipitate if administered at once, highlighting the advantage of CR from the solubility/dissolution point of view. Likewise, segmental-dependent permeability was evident, with higher permeability of carvedilol vs. the low/high P(eff) marker metoprolol throughout the GIT, confirming it as a biopharmaceutical classification system (BCS) class II drug. Theoretical analysis of relevant physicochemical properties confirmed these results as well. A CR product may shift the carvedilol’s solubility behavior from class II to I since only a small dose portion needs to be solubilized at a given time point. The permeability of carvedilol surpasses the threshold of metoprolol jejunal permeability throughout the entire GIT, including the colon, establishing it as a suitable candidate for CR product development. Altogether, this work may serve as an analysis model in the decision process of CR formulation development and may increase our biopharmaceutical understanding of a successful CR drug product. MDPI 2020-03-24 /pmc/articles/PMC7151103/ /pubmed/32214015 http://dx.doi.org/10.3390/pharmaceutics12030295 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Markovic, Milica Zur, Moran Fine-Shamir, Noa Haimov, Ester González-Álvarez, Isabel Dahan, Arik Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development |
title | Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development |
title_full | Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development |
title_fullStr | Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development |
title_full_unstemmed | Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development |
title_short | Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development |
title_sort | segmental-dependent solubility and permeability as key factors guiding controlled release drug product development |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151103/ https://www.ncbi.nlm.nih.gov/pubmed/32214015 http://dx.doi.org/10.3390/pharmaceutics12030295 |
work_keys_str_mv | AT markovicmilica segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment AT zurmoran segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment AT fineshamirnoa segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment AT haimovester segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment AT gonzalezalvarezisabel segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment AT dahanarik segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment |